In the published article, there were two errors made in the Case representation section regarding the dose of pralsetinib.
Firstly, a correction has been made to Case representation, Paragraph 1 on Page 2 of the article. The sentence “He was subsequently treated with pralsetinib (600 mg orally once daily)” has been corrected to “He was subsequently treated with pralsetinib (400 mg orally once daily)”.
Secondly, a correction has been made to Case representation, Paragraph 1 on Page 3. The sentence “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (600 mg orally once daily)” has been corrected to “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (400 mg orally once daily)”.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
RET intergenic fusion, pralsetinib, lung adenocarcinoma, novel intergenic, tyrosine kinase inhibitors
Citation
Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang H-N, Hu Y and Qin H-F (2022) Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient. Front. Oncol. 12:1113289. doi: 10.3389/fonc.2022.1113289
Received
01 December 2022
Accepted
05 December 2022
Published
13 December 2022
Volume
12 - 2022
Edited and reviewed by
Xianquan Zhan, Shandong First Medical University, China
Updates
Copyright
© 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hai-Feng Qin, hifo@263.net; Yi Hu, huyi301zlxb@sina.com
†These authors have contributed equally to this work
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.